98%
921
2 minutes
20
Background: Increasing evidence indicates that microRNA dysfunction is involved in the pathogenesis and progression of cancer. MicroRNA-222 (miR-222) is upregulated in papillary thyroid carcinoma (PTC). However, the role of miR-222 in invasion and metastasis of PTC remains unknown. This study investigated the function of miR-222 and its underlying mechanism in the progression of PTC.
Methods: The expression of miR-222 was detected by quantitative reverse transcription polymerase chain reaction, and its correlation with various clinical characteristics was analyzed. The role of miR-222 in PTC cell migration ability was assessed with Transwell assays and wound-healing assays in both TPC-1 and K1 cells. By using bioinformatics analyses and dual-luciferase 3'-UTR reporter assays, the study identified the direct target of miR-222 and the downstream pathways of PTC. Further, the study confirmed the role of miR-222 in promoting PTC distant metastasis in vivo by injecting TPC-1 cells into nude mice.
Results: This study confirmed that miR-222 was upregulated in PTC tissues compared to adjacent thyroid tissues and that it correlated with aggressive cancer phenotypes. The results indicate that ectopic miR-222 enhanced cell migration and invasion of thyroid cancer cells in vitro and distant pulmonary metastases in vivo. Protein phosphatase 2 regulatory subunit B alpha (PPP2R2A), a tumor suppressor, was identified as a direct target of miR-222 through the 3'-UTR of PPP2R2A. Restoring PPP2R2A expression led to the attenuation of migration and invasion in miR-222-overexpressing thyroid cancer cells. Moreover, we found that miR-222 promoted invasion and metastasis partly through the AKT signaling pathway.
Conclusions: Taken together, the results suggest that miR-222 promotes tumor invasion and metastasis in thyroid cancer by targeting PPP2R2A. Thus, miR-222 could serve as a potential diagnostic biomarker, as well as an attractive therapeutic tool for thyroid cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/thy.2017.0665 | DOI Listing |
Curr Opin Endocrinol Diabetes Obes
October 2025
Department of Surgery, American Mission Hospital, Manama, Bahrain.
Purpose Of Review: To review the current medical evidence in the diagnosis and management of thyroid nodules.
Recent Findings: The widespread use of imaging modalities in recent years has led to frequent discovery of incidental thyroid nodules. These nodules are mostly benign (over 90%), hence precise insight in evaluating nodules of concern and following up other nodules is important to avoid unnecessary surgeries and its complications.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Information Network Center, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Objectives: Increasing detection of low-risk papillary thyroid carcinoma (PTC) is associated with overdiagnosis and overtreatment. N6-methyladenosine (mA)-mediated microRNA (miRNA) dysregulation plays a critical role in tumor metastasis and progression. However, the functional role of mA-miRNAs in PTC remains unclear.
View Article and Find Full Text PDFInt J Hyperthermia
December 2025
Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.
Objective: This study aimed to evaluate the efficacy and safety of US-guided thermal ablation (TA) for solitary papillary thyroid carcinoma (PTC) in elderly patients.
Materials And Methods: This retrospective study included 91 elderly patients with solitary PTC who were treated with TA. The primary outcome was disease progression.
Clin Endocrinol (Oxf)
September 2025
Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Background: Improved cancer survival rates have highlighted second primary malignancies (SPMs), with the thyroid gland being one of the most common organs developing SPMs in cancer survivors. Second primary papillary thyroid carcinoma (2-PTC) is the predominant type, yet it remains poorly understood. This study aims to delineate the clinicopathological features and survival outcomes of 2-PTC and assess the efficacy of postoperative radioactive iodine therapy (post-RAIT) in reducing mortality risks in intermediate-risk 2-PTC patients.
View Article and Find Full Text PDFClin Nucl Med
September 2025
Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide. Immune checkpoint inhibitors (ICI) have improved progression and overall survival in patients progressing on sorafenib therapy. But activation of the immune system can lead to numerous immune-related adverse events.
View Article and Find Full Text PDF